[Antiviral therapy of immunocompromised patients].

For immunocompromised patients virus infections represent a definite risk, particularly infections with measles virus and viruses of the herpes group (primary infections or reactivations). Vidarabine, acyclovir and bromovinyldeoxyuridine are therapeutically active against varicella, zoster, and herpes simplex, provided they are administered early in the course of disease. For zoster at least, the efficacy of interferon has been documented in controlled studies. No convincing therapy is so far available for the severe cytomegalovirus infections. Interferons obtained with DNA recombinant techniques are of significant promise in the near future.
AuthorsH J Eggers
JournalImmunität und Infektion (Immun Infekt) Vol. 12 Issue 4 Pg. 187-91 (Aug 1984) GERMANY, WEST
Vernacular TitleAntivirale Therapie bei resistenzgeschwächten Patienten.
PMID6090308 (Publication Type: English Abstract, Journal Article)
Chemical References
  • Antiviral Agents
  • brivudine
  • Vidarabine
  • Bromodeoxyuridine
  • Acyclovir
  • Acyclovir (therapeutic use)
  • Antiviral Agents (therapeutic use)
  • Bromodeoxyuridine (analogs & derivatives, therapeutic use)
  • Chickenpox (drug therapy, immunology)
  • Cytomegalovirus Infections (drug therapy, immunology)
  • Herpes Simplex (drug therapy, immunology)
  • Herpes Zoster (drug therapy, immunology)
  • Humans
  • Immune System Diseases (complications)
  • Vidarabine (therapeutic use)
  • Virus Diseases (drug therapy, immunology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: